CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-09-09): N-acetylcysteine no help in alcoholic hepatitis

Clinical

N-acetylcysteine no help in alcoholic hepatitis

Last Updated: 2010-09-09 20:01:03 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Addition of the antioxidant N-acetylcysteine confers no extra benefit in patients with severe acute alcoholic hepatitis receiving enteral nutrition, Belgian researchers report in an August 18th on-line paper in the Journal of Hepatology.

Dr. Christophe Moreno of Erasme Hospital, Brussels and colleagues note that there is increasing evidence that oxidative stress is a key mechanism in alcohol-mediated hepatotoxicity. In addition, patients with alcoholic hepatitis are often malnourished.

To examine whether N-acetylcysteine along with nutritional support might be beneficial, the researchers analyzed data on 47 patients who had been randomized to intravenous N-acetylcysteine or placebo. The primary endpoint was 6-month survival.

In both groups when possible, enteral nutrition was given orally. If the patient didn't consume the expected number of calories, placement of a feeding tube was performed. Vitamin supplements were also given. Treatment lasted for 14 days.

At one month, survival was 70.2% in the N-acetylcysteine group and 83.8% in placebo patients. At 6 months, corresponding values were 62.4% and 67.1%. The authors write, however, that the study was underpowered hence the results must be interpreted with caution.

There were also no differences in outcomes including infection rate at 1 month and early biological changes.

Thus Dr. Moreno told Reuters Health by email "we demonstrated that high doses of intravenous N-acetylcysteine therapy for 14 days conferred neither survival benefits nor early biological improvement in severe acute alcoholic hepatitis patients with adequate nutritional support."

The researchers observe that an unscheduled interim analysis was conducted after only half of the initially anticipated number of patients had been included.

"In view of the results," the investigators conclude, "it was decided that there was no point in continuing the study."

SOURCE: http://link.reuters.com/qad62p

J Hepatol 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.